Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis

Summary

The goal of this clinical trial is to study the drug LPX-TI641 in patients with atopic dermatitis and psoriasis. We will compare the safety and tolerability of LPX-TI641 to placebo ( a look-alike solution) that contains no drug. We will also evaluate the plasma pharmacokinetics of LPX-TI641. LPX-TI641 (or placebo) will be administered orally for 28 days.

Timeline

Start

2025-06-15

Primary completion

2026-01-15

Completion

2026-04-15

Drugs

Indications